Technology | ECG Monitoring Services | November 19, 2015

iRhythm Technologies Launches New iOS App for Reporting Irregular Heartbeat Symptoms

Application complements ZIO continuous cardiac monitoring service to provide physicians more complete picture of patient health

iRhythm Technologies, ZIO continuous cardiac monitoring service, myZIO app, irregular heartbeat symptoms, reporting

Image courtesy of iRhythm Technologies

November 19, 2015 — iRhythm Technologies Inc. announced the launch of new patient engagement tools to enhance the diagnosis of cardiac arrhythmias. Patients using the ZIO continuous cardiac monitoring service from iRhythm can now conveniently log heart symptoms with the new myZIO app for iPhone or at myZIO.com.

This new family of smartphone and Web applications is designed to provide additional data for physicians to help rule-in or rule-out arrhythmias sooner in the diagnostic pathway – and adjust the patient's care accordingly.

In addition to allowing patients to digitally record any irregular heartbeat symptoms and associated activities, the myZIO app maximizes a patient's experience with the ZIO Service by providing education, reminders, answering common questions and offering recommendations on the use of the ZIO Patch. Information from the app provides physicians with a more complete picture of the patient's health, allowing for faster and more accurate diagnosis and potentially eliminating the need for additional testing.

Each year, millions of patients see physicians because they feel symptoms that may be caused by an irregular heartbeat, or arrhythmia. The iRhythm ZIO Service allows physicians to diagnose arrhythmias more definitively than via previously available diagnostic technologies, according to iRhythm.

The ZIO Service has the ability to record, store and analyze every heartbeat for up to 14 days, well beyond the 48-hour window of Holter monitoring. Studies of patients wearing the ZIO Patch documented that 50 percent of arrhythmias were diagnosed after 48 hours and that 75 percent of atrial fibrillation patients experienced their longest episode after 48 hours.

"The myZIO app is a great companion to iRhythm's continuous cardiac monitoring service, making it even easier for my patients with suspected cardiac arrhythmias to record their symptoms while wearing the ZIO Patch," said R. Hardwin Mead, M.D., partner and co-founder at Silicon Valley Cardiology in East Palo Alto, Calif. "Such a discreet and convenient way to track symptoms gets the patient intimately involved in the diagnostic process. Combining that additional valuable information with the 20,000 minutes of heartbeat data captured by the ZIO Patch will provide me an even more robust clinical arrhythmia interpretation."

The myZIO iOS app is available for download from the Apple App Store. myZIO is also available as a web application for non-iPhone users at myZIO.com.

For more information: www.irhythmtech.com

Related Content

FDA Clears AliveCor's KardiaMobile 6L as First Six-Lead Personal ECG Device
Technology | ECG | May 13, 2019
AliveCor announced its third U.S. Food and Drug Administration (FDA) clearance in three months, making KardiaMobile 6L...
One innovation in ECG is its use in the customer wearable market, which will tie more closely into the clinical world either with using the data to triage patients and/or patients seeking medical attention prior to acute symptoms appearing.

One innovation in ECG is its use in the customer wearable market, which will tie more closely into the clinical world either with using the data to triage patients and/or patients seeking medical attention prior to acute symptoms appearing.

Feature | ECG | May 03, 2019 | Sanket Solanki
Technology has made its way into the healthcare sector and brought a drastic transformation.
Videos | ECG | March 05, 2019
This is a quick demo of the Schiller Cardiovit FT-1 electrocardiograph (ECG) system displayed at the ...
EKG With Artificial Intelligence Reliably Detects Heart Failure Precursor
News | ECG | January 08, 2019
January 8, 2019 — A Mayo Clinic study finds that applying...
Use of traditional Holter monitor leads can be an issue for patient compliance and comfort. The newer generation ambulatory cardiac monitors use an adhesive patch that sticks directly on the patient's chest and allows them to shower and go about daily activities without a belt mounted monitor or leads getting in the way. This is especially important for longer term monitoring of seven days or longer.

Use of traditional Holter monitor leads can be an issue for patient compliance and comfort. The newer generation ambulatory cardiac monitors use a small, adhesive patch that sticks directly on the patient's chest and allows them to shower and go about daily activities without a belt mounted monitor or leads getting in the way. This is especially important for longer term monitoring of seven days or longer. 

Feature | ECG | September 27, 2018
Advances in the technology of wearable cardiac monitors are improving both the experience of the patient and the effe
HeartSciences MyoVista ECG Device Shows Promise in Detecting Abnormal Cardiac Function
News | ECG | April 27, 2018
HeartSciences announced the results of a clinical study of its electrocardiography device that applies continuous...
ECG Study of NBA Players Shows Need for Sport-Specific Normative Data and Guidelines
News | ECG | December 08, 2017
Cardiologists at NewYork-Presbyterian/Columbia University Irving Medical Center compared electrocardiographic findings...
HeartSciences Announces CE Mark and European Launch of MyoVista High Sensitivity ECG

Just as a Doppler radar color image shows the energy of a storm, MyoVista provides physicians a detailed visual image of the energy distribution during the cardiac cycle.

News | ECG | August 22, 2017
HeartSciences announced the European launch of the MyoVista high sensitivity electrocardiograph (hsECG) Testing Device...
AUM Cardiovascular Receives FDA Approval for CADence ECG Device
Technology | ECG | August 08, 2017
AUM Cardiovascular announced it has received clearance from the U.S. Food and Drug Administration (FDA) for CADence, a...
More Than 20 Percent of Low-Risk Patients Receive Annual ECG
News | ECG | July 20, 2017
July 20, 2017 — More than one in five Ontario patients receive an ...
Overlay Init